Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
This randomized control trial of over 4000 high risk patients with Type 2 diabetes and eGFR > 30 ml/min, empagliflozin (a sodium-glucose cotransporter 2 inhibitor) when compared with placebo was associated with slower progression of kidney disease (12.7% vs 18.8% for worsening nephropathy and 1.5% vs 2.6% for doubling of serum creatinine) when added to the standard of care. Renal replacement therapy was initiated in 0.3% of the treatment group vs 0.6% of the placebo group (55% lower relative risk).
:
Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Chronic Kidney Disease Clinical Nephrology Clinical Trial Results Diabetes General Nephrology Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Type 1 | Diabetes Type 2 | Diovan | Empagliflozin | Endocrinology | Heart | Jardiance | Polycystic Kidney Disease | Urology & Nephrology